Research Paper Volume 11, Issue 23 pp 11010—11029

Figure 2. The relationship between recurrence score and clinical pathologic characteristics of GBM. (A) The heatmap presented PFS days, clinical pathology, and 6 representative genes of ROS for each GBM patient in ascending order of the recurrence score. PFS days, transcriptome subtype, and 6 ROS related genes showed asymmetry distribution. (B, F) The recurrence score showed no significant difference in different genders in the TCGA and CGGA databases. ^NSp>0.05. (C, G) Age showed no significant difference in recurrence risk groups in TCGA database. NS means p>0.05. Patients in the high risk recurrence group were older than the low risk group. ^**p<0.01. (D, H) The mesenchymal and neural subtypes showed significant higher recurrence scores in th TCGA and CGGA databases. ^NSp>0.05, ^**p<0.01, ^***p<0.001, ^****p<0.0001. (E, I) The recurrence score showed no significant difference in different MGMT promoter status GBM samples in TCGA and CGGA databases. ^NSp>0.05.